Outcome of stroke patients receiving different doses of recombinant tissue plasminogen activator - Wikidata - awgldk - TriplyDB

Outcome of stroke patients receiving different doses of recombinant tissue plasminogen activator

Outcome of stroke patients receiving different doses of recombinant tissue plasminogen activator

http://www.wikidata.org/entity/Q33719200

about

Efficacy and safety of low dose alteplase for intravenous thrombolysis in Asian stroke patients: a meta-analysis.Cerebral Hypoperfusion and Other Shared Brain Pathologies in Ischemic Stroke and Alzheimer's Disease.

P2860

Q47147347-2FB18A2E-D33B-4DDC-B202-D4BE40B2068A Q47711014-89024948-CF3D-4EF0-B9CE-D51661015FF8

P2860

Outcome of stroke patients receiving different doses of recombinant tissue plasminogen activator

http://www.wikidata.org/entity/Q33719200

description

2017 nî lūn-bûn

@nan

2017 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2017 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

name

Outcome of stroke patients rec ...... t tissue plasminogen activator

@ast

Outcome of stroke patients rec ...... t tissue plasminogen activator

@en

type

label

Outcome of stroke patients rec ...... t tissue plasminogen activator

@ast

Outcome of stroke patients rec ...... t tissue plasminogen activator

@en

prefLabel

Outcome of stroke patients rec ...... t tissue plasminogen activator

@ast

Outcome of stroke patients rec ...... t tissue plasminogen activator

@en

P1433

Q33719200-61AE3C3F-3986-42DF-9308-01362B30141C

P1476

Q33719200-52F12EBC-D2E5-49F6-AFDC-3D6087631310

P2093

Q33719200-318AE5FB-054E-4166-A163-811DD11920DA

Q33719200-B7264045-4D8E-4003-8A0A-088BA73BFD1D

Q33719200-B78777A5-2E9A-46D5-A115-0666B0206F9A

Q33719200-CFB3AFD9-A2FC-4D0E-BAE0-24E3918D5CBD

P2860

Q33719200-0AC72674-C6BB-496A-95B2-70B0A7E0B5A5

Q33719200-139D54C8-6B41-4AF5-BF31-F9B1B7159C16

Q33719200-14E7F6C1-F5C8-4EAE-A1D3-88A398F92E66

Q33719200-30C8A682-33BD-4086-A9F3-9105DB9EE8A6

Q33719200-3504FD25-3116-45EC-9234-25D5993815BA

Q33719200-413E0175-5F7B-41B0-B45C-061AFF4EBFC5

Q33719200-5A5B696B-9C6D-4EA2-8908-9D91DB1447B8

Q33719200-62E9B3E4-FCE4-47AB-A0A0-C9FF6C4A730C

Q33719200-72CBF9A8-BADB-42FF-B201-F62158593660

Q33719200-7C3EABB1-CE38-4E64-90A7-488E6DBF8762

P304

Q33719200-36E5D7A9-C3F8-470F-99FF-DFBE55B5B3F4

P31

Q33719200-ACC6F8A7-0B09-4EF6-978B-DFC2044DE1BF

P356

Q33719200-E4AD65E4-D6C7-4B39-8B25-38ED4AEA81BB

P407

Q33719200-50C84788-965E-4A61-A68D-F365CED3E8E9

P478

Q33719200-431ECF2A-C4D2-431C-A227-113A5FD87046

P577

Q33719200-73AFEFE1-0F19-4D5A-9A4F-134783781448

P698

Q33719200-37D0FAD6-D6BB-4C5A-890B-66D7528B21B1

P932

Q33719200-8B28C0A6-2155-48A1-B1A8-D883BB85F40E

P356

P1433

Drug Design, Development and Therapy

P1476

Outcome of stroke patients rec ...... t tissue plasminogen activator

@en

P2093

Cheung-Ter Ong

http://www.w3.org/2001/XMLSchema#string

Chi-Shun Wu

http://www.w3.org/2001/XMLSchema#string

Yi-Sin Wong

http://www.w3.org/2001/XMLSchema#string

Yu-Hsiang Su

http://www.w3.org/2001/XMLSchema#string

P2860

Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke

Impact of hyperlipidemia and statins on ischemic stroke outcomes after intra-arterial fibrinolysis and percutaneous mechanical embolectomy.

Defining clinically relevant cerebral hemorrhage after thrombolytic therapy for stroke: analysis of the National Institute of Neurological Disorders and Stroke tissue-type plasminogen activator trials.

The safety and effectiveness of low-dose recombinant tissue plasminogen activator (0.6 mg/kg) therapy for elderly acute ischemic stroke patients (≥ 80 years old) in the pre-endovascular era

IV thrombolysis in very severe and severe ischemic stroke: Results from the SITS-ISTR Registry.

Reperfusion half-life: a novel pharmacodynamic measure of thrombolytic activity.

Low vs standard dose of recombinant tissue plasminogen activator in treating East Asian patients with acute ischemic stroke.

Race/Ethnic differences in the risk of hemorrhagic complications among patients with ischemic stroke receiving thrombolytic therapy.

Low-Dose versus Standard-Dose Intravenous Alteplase in Acute Ischemic Stroke.

Alteplase at 0.6 mg/kg for acute ischemic stroke within 3 hours of onset: Japan Alteplase Clinical Trial (J-ACT).

P304

1559-1566

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/DDDT.S133759

http://www.w3.org/2001/XMLSchema#string

P407

P478

11

http://www.w3.org/2001/XMLSchema#string

P577

2017-05-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28572721

http://www.w3.org/2001/XMLSchema#string

P932

5441661

http://www.w3.org/2001/XMLSchema#string